Monashee Investment Management LLC Has $2.41 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Monashee Investment Management LLC trimmed its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 77.8% during the 1st quarter, HoldingsChannel reports. The firm owned 50,000 shares of the company’s stock after selling 175,000 shares during the quarter. Structure Therapeutics accounts for 1.3% of Monashee Investment Management LLC’s investment portfolio, making the stock its 25th biggest holding. Monashee Investment Management LLC’s holdings in Structure Therapeutics were worth $2,410,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Structure Therapeutics by 18.5% in the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after purchasing an additional 8,444 shares in the last quarter. Invesco Ltd. boosted its position in shares of Structure Therapeutics by 7.6% in the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after buying an additional 30,162 shares during the period. Marshall Wace LLP grew its holdings in shares of Structure Therapeutics by 474.9% during the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after buying an additional 145,434 shares in the last quarter. Jump Financial LLC grew its holdings in shares of Structure Therapeutics by 105.9% during the second quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after buying an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in Structure Therapeutics during the second quarter valued at $3,480,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GPCR. Wall Street Zen downgraded Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. Wolfe Research began coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. HC Wainwright reduced their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $110.55.

Structure Therapeutics Trading Up 2.1%

NASDAQ GPCR opened at $50.41 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $15.80 and a 1-year high of $94.90. The firm’s fifty day simple moving average is $44.99 and its 200-day simple moving average is $56.02. The company has a market capitalization of $3.58 billion, a PE ratio of -57.94 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. As a group, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.